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1. Introduction
Brainstem gliomas are a heterogeneous group of tumors occurring in the brainstem and
cervicomedullary junction.  They occur  more  often in  children than in  adults.  Brainstem
tumors,  according  to  data  prior  to  early  1980s,  represent  10-20% of  all  central  nervous
system neoplasms in the pediatric population [1-3]. Approximately 90% of brainstem tu‐
mors are gliomas in origin [4].
Diffuse intrinsic pontine glioma (DIPG) is the most common type representing approximate‐
ly 80% of brainstem gliomas [5, 6]. They have a dismal prognosis with a median survival of
only a year. Their natural history is often compared to but worse than that of supratentorial
glioblastoma seen primarily in the adult population. Nondiffuse brainstem gliomas, includ‐
ing focal, dorsal exophytic and cervicomedullary gliomas, are encountered less often and
have a better prognosis. However, if untreated, they could also lead to progressive brain‐
stem dysfunction and ultimately death.
2. Epidemiology
True incidence studies of brainstem gliomas are lacking. According to the Central Brain Tu‐
mor Registry of the United States, there were 400-450 cases of brainstem gliomas in children
per year in the U.S. during 2004-2008, representing 10.7% of primary central nervous system
tumors [7]. This number is higher than those previously estimated for the period between
1970s-1990s [8]. The increase is thought primarily to be a result of increased detection by the
use of magnetic resonance imaging (MRI) and better data reporting as opposed to a true in‐
crease in the incidence of these tumors.
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The most common age at diagnosis for DIPG is 5-9 years old with a median of 6.5 years, but
cases have been seen in all age groups from infants to adults [5, 9]. Nondiffuse brainstem
gliomas have roughly the same age distribution.
Neurofibromatosis type 1 (NF1) patients have higher incidence of brainstem gliomas. These
tumors, whether diffuse or nondiffuse, appear to have a more benign course compared with
tumors from patients without NF1 [10].
There does not appear to be a sex predilection in any of the brainstem tumor subgroups [5,
9]. Because of the low incidence and lack of diagnosis in less developed countries, there is
not sufficient data to determine if there is a geographic propensity. No specific risk factors,
either environmental or infectious, have been described to be related to the incidence of
brainstem gliomas.
3. Classification
Brainstem gliomas are classified based on their location, focality and growth patterns. Clas‐
sification systems were created using the current form of imaging available. Brainstem glio‐
mas can be broadly categorized as diffuse intrinsic pontin glioma (DIPG) and nondiffuse
brainstem gliomas. Nondiffuse brainstem gliomas can be further classified into three
groups: focal gliomas (tectal and other locations), dorsal exophytic gliomas and cervicome‐
dullary gliomas.
DIPG accounts for approximately 80% of brainstem gliomas in children [5, 6]. Surgical resec‐
tion is not possible due to the location and infiltrative nature of the tumor. The standard of
care for DIPG is radiation therapy. They have a median survival of about 10-12 months [6].
Focal gliomas account for about 5% of brainstem gliomas in children. They may be located
anywhere within the brainstem but are typically not in the ventral pons. Most focal gliomas
occur in the midbrain, especially the tectum of the midbrain. Focal gliomas in other areas of
the brainstem, such as medulla, are less often seen. As a result, some discussions about focal
gliomas may focus on tectal gliomas. Focal gliomas have well defined margins. They usually
have an indolent course, and depending on location, are often amenable to surgical resec‐
tion. The majority of tectal glioma patients have non-communicating hydrocephalus at ini‐
tial presentation due to compression of cerebral aqueduct. Focal gliomas have a good
prognosis [11].
Dorsal exophytic gliomas account for 10-15% of brainstem gliomas in children. They present
insidiously with a long history of nonspecific headache and vomiting. They are amenable to
surgical resection. These tumors have a good outcome after surgical resection [12].
Cervicomedullary gliomas account for 5-10% of brainstem gliomas in childrens. They arise
from the lower medulla or the upper cervical spinal cord. They are amenable to surgical re‐
section. Long-term tumor control can be achieved in most patients with surgical resection
alone [13, 14].
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4. Pathology and pathophysiology
Brainstem gliomas are typically astrocytomas. Focal, dorsal exophytic and cervicomedullary
gliomas are usually pilocytic astrocytoma (WHO grade I) and fibrillary astrocytoma (WHO
grade II). Other low-grade gliomas with indolent growth such as ganglioglioma are also
seen. DIPGs are typically anaplastic astrocytoma (WHO grade III) and glioblastoma multi‐
forme (WHO grade IV). Growth of low-grade gliomas typically respect fiber tracts and pial
borders. In contrast, high-grade gliomas grow and expand without respecting anatomic
boundaries of these surrounding tissues.
70-90% of DIPGs are anaplastic astrocytoma (WHO grade III) and glioblastoma multiforme
(WHO grade IV) if biopsied before radiation therapy is given [15-17]. The remainders are
mainly fibrillary astrocytoma (WHO grade II). At a later stage, invasion of adjacent levels of
the brainstem and cerebellar peduncles is common. At autopsy, the vast majority of DIPGs
are high-grade and more than 50% have disseminated within the neuraxis [18].
Most focal gliomas are low-grade [11, 19]. Low-grade gliomas seen in this subgroup include
pilocytic astrocytoma, fibrillary astrocytoma and ganglioglioma. Most tectal gliomas cause
hydrocephalus at an early stage due to its compression on the cerebral aqueduct.
Dorsal exophytic gliomas arise from subependymal glial tissue. Over 90% of these tumors
are pilocytic astrocytomas [20] that grow along the path of least resistance. As a result, most
of the tumor extends into the fourth ventricle rather than infiltrating the brainstem ventrally.
Tumors that extend laterally and/or ventrally into the brainstem are usually more aggressive
and of higher grade on pathological examination.
Cervicomedullary  gliomas  arise  from either  the  lower  medulla  or  upper  cervical  spinal
cord.  Most  of  them are  low-grade astrocytomas,  but  gangliogliomas and ependymomas
are also seen [14,  21].  Tumors with epicenters  in the upper cervical  cord grow dorsally
into the cisterna magna.  Those with epicenters  in the lower medulla  grow centrifugally
as focal nodules.
5. Molecular genetics
Partially because of the low incidence of brainstem gliomas, their molecular genetics is less
studied compared with some more common primary central nervous system tumors. How‐
ever, there are some significant advances in the last a few years concerning both DIPG and
focal brainstem gliomas.
DIPGs are genetically complex and distinct from both adult and pediatric supratentorial
high-grade gliomas (HGG). Recent evidence points to platelet-derived growth factor (PDGF)
and its receptors (PDGFR) as among the major driving forces of tumorigenesis in the majori‐
ty of cases [22-26]. Another type of growth factor receptors involved in DIPG is epidermal
growth factor receptor (EGFR). Expression of EGFR was reported in the majority of high
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grade and less than 20% of low grade DIPG by immunohistochemistry staining [27]. The
same study also reported that 25% of grade III and 50% of grade IV tumors had EGFR gene
amplification. Recent data show that strong EGFR immunohistochemistry staining was seen
in about 27% cases [23], lower than in the earlier report, and that amplification rate of the
EGFR gene is also much lower (about 7-9%) [23, 25]. Unlike the case in pediatric supratento‐
rial HGG, CDKN2A deletion is non-existent in DIPG [25, 28] and amplification of CDK4 and
CDK6 only occurs at a low rate [25]. Approximately 50% of DIPG had p53 mutation [29, 30]
and three groups reported loss of a region of 17p containing the p53 gene in 31%, 57% and
64% cases, respectively [23, 28, 31]. In approximately 50% of DIPG patients, allelic loss of a
region of 10q where PTEN is located was observed [31-33].
There  have been fewer  molecular  genetics  studies  of  nondiffuse  brainstem gliomas.  Re‐
cently  it  was  reported that  BRAF gene  duplication and mutation are  often  observed in
pediatric  pilocytic  astrocytomas  and  fibrillary  astrocytomas,  including  those  located  in
the brainstem [34-36].
6. Clinical presentation
The clinical behavior and presentation of brainstem gliomas are highly variable, depending
on the anatomic location and growth pattern of the tumor, age of the patient and certain oth‐
er factors. Symptom evolution reflects aggressiveness of the tumor. Low-grade tumors typi‐
cally present with an insidious course over several months of gradual symptom progression.
By comparison, a shorter and more abrupt onset of symptoms is indicative of higher-grade
tumors.
Nondiffuse gliomas are often low-grade lesions with expectedly slow growth. Symptoms
are insidious in onset and may not be readily appreciated. Careful history taking, including
comparison to photographs, may be necessary to evaluate subtle changes associated with
cranial nerve dysfunction in these slow-growing tumors. DIPGs, in comparison, typically
present with a short prodrome of symptoms (usually 1-2 months or shorter) [9].
In brainstem gliomas, the pattern of symptoms reflects the extent of the tumor. Diffusely
growing tumors are associated with multiple and bilateral cranial neuropathies, long tract
signs and ataxia. Hydrocephalus in these tumors is uncommon at initial presentation. Non‐
diffuse gliomas often present with isolated cranial neuropathies, signs and symptoms of in‐
creased intracranial pressure, and ataxia. Rarely, hemiparesis may be part of the clinical
presentation.
Brainstem glioma patients can have a combination of the following at presentation.
Cranial neuropathies are common in most tumors of the brainstem. Simultaneous involve‐
ment of multiple cranial nerves is more frequently encountered with diffuse lesions. Focal
lesions, in contrast, are often associated with more limited cranial nerve involvement. Upper
brainstem involvement is often associated with oculomotor deficits, and lesions of the lower
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brainstem are frequently found to have lower cranial nerve involvement resulting in
changes in voice, dysphagia and/or aspiration pneumonias.
Long tract signs, including motor dysfunction and hyperreflexia, are most often associated
with diffusely growing tumors or focal tumors of the cervicomedullary junction. Long tract
signs are often conspicuously absent with dorsal exophytic gliomas [12].
In brainstem glioma patients, ataxia can be a result of loss of proprioceptive sensation, CN
VIII involvement and/or invasion of cerebellar peduncles by the tumor. Ataxia is frequently
seen in DIPG patients.
Obstructive hydrocephalus is usually the first sign seen in focal tectal gliomas as a result of
the tumor compressing cerebral aqueduct. Hydrocephalus and its associated signs and
symptoms are also often seen in dorsal exophytic gliomas which grow dorsally into the
fourth ventricle resulting in the obstruction of normal cerebrospinal fluid (CSF) flow.
Failure to thrive is commonly encountered in infants with tumors of the cervicomedullary
junction due to lower cranial nerve dysfunction resulting in swallowing difficulties.
6.1. Diffuse intrinsic pontine gliomas
DIPG patients usually have an acute onset and present with a history of rapid deterioration
of 1-2 months or even shorter. Physical examination reveals classic brainstem signs: cranial
nerve deficits, long tract signs and ataxia, or combinations of the three. At least two of the
triad need to be present along with MRI evidence to establish the diagnosis of DIPG.
Bilateral and multiple cranial nerve involvement is frequent in DIPG. Abducens (CN VI)
palsy is the most frequent cranial neuropathy at presentation [5]. Facial palsy is also fre‐
quently seen at initial presentation. Involvement of CN VIII causes deadness and contrib‐
utes to ataxia. Lower cranial nerve involvement causes aspiration, and difficulty in speech,
swallowing and maintaining normal head positions.
These  children  often  present  with  severe  limb weakness  and hyperreflexia,  resulting  in
their  difficulty  to  walk  and  sometimes  even  to  sit.  Long  tract  involvement  also  causes
loss  of  tactile,  nociceptive  and proprioceptive  sensations,  causing  numbness  and contri‐
buting to ataxia.
In DIPG patients, both CN VIII involvement and loss of proprioceptive sensation contribute
to ataxia. Invasion of cerebellar peduncles is also common in DIPG, which is another factor
contributing to ataxia.
DIPG patients may also have other symptoms including headache, nausea and vomiting etc.
indicating increased intracranial pressure from edema or hydrocephalus. Approximately
10% of DIPG patients have hydrocephalus at initial presentation [5].
6.2. Focal gliomas
Focal gliomas can occur anywhere in the brainstem, but usually not in the vental pons. Their
clinical presentations depend on the location.
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Focal tectal gliomas have an insidious clinical course and often compress on cerebral aque‐
duct to cause a non-communicating hydrocephalus [11, 37]. As a result the initial presenta‐
tion is usually those signs reflecting increased intracranial pressure: headache, vomiting,
diplopia and papilledema.
Focal gliomas in the midbrain tegmentum and the medulla are usually larger than tectal
gliomas and presents with cranial nerve dysfunction, long tract signs and ataxia [11, 38].
6.3. Dorsal exophytic gliomas
Dorsal exophytic gliomas grow into the fourth ventricle and typically present with signs
and symptoms of increased intracranial pressure including headache, nausea and/or vomit‐
ing, lethargy, downward gaze preference, changes in vision and cranial nerve palsies (in‐
cluding abducens palsy). Infants with these tumors may present primarily with failure to
thrive. Long tract signs are rare with these tumors [12].
6.4. Cervicomedullary gliomas
Cervicomedullary gliomas usually have an indolent course because the majority of these tu‐
mors are slow growing low-grade lesions. Two presenting syndromes have been described
based on the epicenter of these tumors [39]. Medullary syndrome often presents as a failure
to thrive secondary to nausea, vomiting or dysphagia. Also seen with this syndrome are
sleep apnea, dysarthria and recurrent upper respiratory tract infections. Cervical cord syn‐
drome presents with chronic neck pain and/or progressive myelopathy with spasticity and
weakness. Hydrocephalus is unusual in cervicomedullary gliomas.
7. Imaging studies
Diagnosis of brainstem gliomas is based on clinical presentations and imaging studies. MRI
is the imaging method of choice because of its high resolution and ability to differentiate the
natures of lesions (tumor vs. inflammation etc.), which is especially important in the diagno‐
sis of DIPG. MRI enables identification of important anatomic features and localization of
tumors with multi-planar views. It allows a precise evaluation of the growth pattern and ac‐
curate preoperative diagnosis in most cases. Both T1- and T2-weighted axial and sagittal se‐
quences should be obtained for the basic studies. Other useful sequences include fluid
attenuated inversion recovery (FLAIR), diffusion tensor imaging (DTI), gradient echo (GRE)
and susceptibility weighted imaging (SWI). DTI tractography may be useful in evaluating
the relationship between the tumor and white matter tracts [40], which can be a part of the
preoperative planning for nondiffuse brainstem gliomas.
7.1. Diffuse intrinsic pontine gliomas
DIPGs are diagnosed with clinical presentation and magnetic resonance imaging. Since the
publication of the Children's Cancer Group (CCG) report in 1993 [41], when a brainstem tu‐
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors396
mor presents with typical symptoms and radiological appearance, it is usually considered
that these findings are diagnostic and a biopsy is rarely performed. If, however, the clinical
or radiological presentation is not typical, where brainstem encephalitis or an inflammatory
process of the pons cannot be ruled out, a stereotactic biopsy would be needed before initiat‐
ing radiation therapy and/or chemotherapy.
DIPGs infiltrate widely. MRI scans show infiltrative expansion of the pons that is typical‐
ly  hypointense  on  T1-weighted,  hyperintense  on  T2-weighted  and  FLAIR  images,  and
has  no  significant  dorsal  exophytic  component.  Involvement  of  adjacent  levels  of  the
brainstem and/or  cerebellar  peduncles  is  common.  Envelopment  of  the  basilar  artery  is
commonly present  in  DIPG showing the  tumor growing ventrally  outside  of  the  boun‐
dary  of  the  brainstem.  Contrast  enhancement  with  gadolinium is  variable,  with  no  en‐
hancement  being  common  [42].  Enhancement,  if  present,  is  usually  patchy,  without
known prognostic  significance.  Neuraxis  dissemination of  DIPG can be seen on MRI in
more than 50% of patients during progression [18].  In some cases the tumor may show
atypical  features  including  prominent  enhancement  and/or  hypointense  T2-weighted/
FLAIR signals.
Magnetic resonance spectroscopy (MRS) is helpful in differential diagnosis when the tumor
shows atypical features. Increased Cho/NAA (choline/N-acetyl aspartate) and Cho/Cr (chol‐
ine/creatine) ratios in DIPG are useful in differentiating it from brainstem encephalitis, de‐
myelination and other inflammatory processes when clinical and MRI presentations are
atypical [43, 44]. However, the differentiating power of MRS is limited in NF1-associated
DIPG [43].
7.2. Focal gliomas
Before the availability of computed tomography (CT) and MRI for the diagnosis of intracra‐
nial lesions, focal tectal gliomas could only be found in autopsy evaluations. In the 1950s,
when CSF diversion procedures were not as universally successful as of today, Kernohan
and Sayre stated that tectal gliomas were “in all probability the smallest tumors in the hu‐
man body that lead to the death of the patient [45].”
Focal gliomas show as focal lesions on MRI. Focal tectal gliomas are usually isointense on
MRI and show as thickened tectal plate. Tectal gliomas rarely enhance with gadolinium [11,
37]. Central calcification may be noted rarely [46]. Hydrocephalus is seen in the vast majori‐
ty of tectal gliomas, causing symptoms for which the patients are seeking medical attention.
Focal gliomas in other areas of the brainstem are usually hypointense on T1-weighted and
hyperintense on T2-weighted images. The margins are well defined in focal tegmentum and
medullary gliomas, and most are more or less round or spherical. They are frequently cystic
with an intense rim enhancement after intravenous contrast agent administration. Most
midbrain focal gliomas show upward extension to the thalamus and downward extension to
the pons.
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7.3. Dorsal exophytic gliomas
Dorsal exophytic gliomas typically erupt through the pia/ependyma early in their growth,
so imaging will show that the bulk of tumor outside of the brainstem. Imaging of patients
suspected of dorsal exophytic gliomas should include MRI studies with and without intra‐
venous gadolinium of the brain to differentiate this type of tumor from tumors in the fourth
ventricle such as primitive neuroectodermal tumors (PNETs). On MRI, dorsal exophytic
gliomas appear as a dorsal exophytic expansion into the fourth ventricle or below the cere‐
bellum. They usually show as sharply demarcated hypointense signals on T1-weighted and
hyperintense on T2-weighted images. Bright homogeneous contrast enhancement and hy‐
drocephalus are common MRI findings [20].
7.4. Cervicomedullary gliomas
Imaging of patients suspected cervicomedullary gliomas should include MRI studies with
and without intravenous gadolinium of the brain and cervical spine to determine the extent
of tumor growth and involvement.
Cervicomedullary gliomas arise from either the lower medulla or upper cervical spinal cord.
Growth pattern of the tumor will give some hints as to their epicenters and what structures
are being placed at risk by tumor growth. Tumors with epicenters in the upper cervical cord
will have their rostral growth blocked by the decussating fibers of the sensory and motor
pathways. Instead, the tumor curves dorsally to grow into the cisterna magna at the cervico‐
medullary junction. Tumors with epicenters in the lower medulla grow centrifugally as focal
nodules pushing the surrounding fibers to their side [21].
Cervicomedullary gliomas appear as solid masses within the above-described areas. They
are hypointense on T1-weighted and hyperintense on T2-weighted images. They typically
enhance homogeneously upon gadolinium injection.
8. Diagnosis and differential diagnosis
Diagnosis of brainstem gliomas is based on clinical presentations and imaging studies and
needs to address the location and nature of the lesion.
It is expected that the patient's clinical course, examination and imaging studies be in agree‐
ment. With nondiffuse brainstem gliomas this congruence often prompts surgical interven‐
tion (resection and/or relief of hydrocephalus), particularly for those located at the
cervicomedullary junction or dorsal exophytic in growth.
Incongruence between presentation and clinical studies suggests the need for biopsy prior
to definitive treatment. In cases with disagreement between the imaging findings and clini‐
cal course (i.e. rapidly progressive course with imaging consistent with a focal or low-grade
lesion), frozen sections should be obtained at the time of surgery prior to progressing to an
aggressive resection. These instances may be representative of a more malignant tumor in
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which case the potential for iatrogenic injury during resection outweighs the potential bene‐
fit of an extensive resection.
Differential diagnosis includes other tumors in the brainstem and adjacent regions and le‐
sions of other natures. Other tumors include lymphoma, metastatic tumors, germinoma and
nongerminomatous germ cell tumors, PNET, hemangioblastoma, lipoma, acoustic neuroma,
etc. Some of these tumors typically arise from nearby regions and may encroach into the
brainstem, e.g., primary intracranial germ cell tumors usually occur in the pineal region and
can invade the brainstem. The majority of nongerminomatous germ cell tumors can be dif‐
ferentiated by testing for secreted markers in the blood such as α-fetoprotein and β-human
chorionic growth hormone. PNET occurring in the brainstem, even though relatively rare,
can appear similar to DIPG or nondiffuse brainstem gliomas. Because of the difference in
treatment options from those for brainstem gliomas, it should be carefully differentiated
when suspected. Lesions of other natures include infectious, autoimmune, other inflamma‐
tory, vascular and metabolic lesions etc.
The role of biopsy in the diagnosis of DIPG remains intensely debated [47, 48]. Before the
wide adoption of MRI in the diagnosis of brainstem gliomas, biopsy was performed to con‐
firm diagnosis and provide information on prognosis. However, biopsy has been only per‐
formed infrequently since mid-1990s. Of note is that since the Children's Cancer Group
(CCG) report in 1993 [41], MRI has superseded biopsy as the main method of diagnosing
DIPG. As better methods to characterize tumors become available and more molecularly tar‐
geted therapies have become available or are under development in recent years, there are
increasing calls to perform biopsy more frequently in clinically diagnosed DIPGs. Brainstem
biopsy is safe with low morbidity and mortality rates [49-51]. Survey showed that parents of
children with DIPG are generally amenable to biopsy, even if the results may not benefit the
patient [52]. Various focus groups have been holding discussions on criteria of recommend‐
ing biopsy. Some investigational protocols of DIPG have included biopsy and molecular
characterization as mandatory components in stratifying subjects for experimental therapy.
9. Treatment
Treatment of brainstem gliomas includes management of pain, bulbar symptoms and motor
impairment, relief of hydrocephalus and general support. Brainstem glioma patients should
be cared for by a multidisciplinary team including neurosurgeons, non-surgical specialists
and other therapists.
Surgical intervention is indicated for certain nondiffuse brainstem gliomas. Tectal gliomas
are usually indolent and present with hydrocephalus. Hydrocephalus is relieved by endo‐
scopic third ventriculostomy (ETV) or ventricular shunt placement. Early resection of tectal
gliomas is controversial. Dorsal exophytic gliomas are the most amenable to surgical resec‐
tion in brainstem gliomas. The goal is to remove the exophytic component, and when safe,
followed by debulking of the intrinsic component. Surgical resection is typically recom‐
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mended early for cervicomedullary gliomas. Subtotal resection can be safely performed in
most cases.
Adjuvant therapy for brainstem gliomas depends on the tumor location, pathological diag‐
nosis and extent of previous surgical resection. Radiation therapy is the standard of care for
DIPG, but it is not recommended as an early treatment for nondiffuse brainstem gliomas if
pathology shows a low-grade glioma. It is usually used in patients with high-grade patholo‐
gy, upon clinical and imaging evidence of progression, or late in the disease course [5, 38].
Stereotactic radiosurgery is also used in nondiffuse brainstem gliomas. Chemotherapy has
limited use in the management of brainstem gliomas. It is mainly used for high-grade path‐
ology or at late stage of the disease.
9.1. Diffuse intrinsic pontine glioma
Surgical resection of DIPG is not safe because of its location and infiltrative nature. Biopsy is
not indicated for patients with typical clinical presentation and MRI findings. Hydrocepha‐
lus, if present, should be treated with either an ETV or a shunt. A histological confirmation
might be needed if imaging or clinical history is not typical for a DIPG, or if an investiga‐
tional protocol requests it.
The standard of care for DIPG is involved field external beam radiation therapy, typical‐
ly delivered at 1.8Gy/fraction for 30-33 fractions in the North America. Significant clinical
improvement occurs in 85% of patients receiving radiation therapy, but the improvement
is usually transient,  lasting only 3-4 months,  before progressive decline in clinical status
returns [6].
Various chemotherapeutic regimens have been studied either alone or in combination with
radiation therapy. However, up to date, no chemotherapeutic agent, either alone or in com‐
bination, or in conjunction with radiation therapy, has altered the natural history of DIPG.
Many patients are enrolled in clinical trials of new agents or previously used agents in pre‐
viously untested combinations.
9.2. Focal gliomas
Most tectal gliomas in children have indolent growth with few symptoms except those
caused by hydrocephalus. Early resection of focal tectal gliomas is controversial and infre‐
quently done. Often, these tumors are managed by relief of hydrocephalus, followed by clin‐
ical observation and periodic MRI scans [53, 54]. Treatment of the hydrocephalus typically
includes ETV to restore CSF flow. Shunting is an alternative or can be considered for pa‐
tients who fail ETV. Surgical resection may be considered on rare occasions.
Focal gliomas in other areas of the brainstem, including tegmentum and medulla, are usual‐
ly indicated for surgical resection. Tissue diagnosis before radical resection is indicated for
lesions with atypical clinical and imaging findings. For those patients initially put on obser‐
vation, when tumor progression is observed, biopsy or sometimes radical resection is indi‐
cated. Transventricular endoscopic biopsy may be performed with or without CSF diversion
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when the tumor is adjacent to a ventricle’s walls [55]. Stereotactic biopsies may be consid‐
ered for lesions that cannot be approached with endoscopy where accurate histological diag‐
nosis is warranted but more aggressive surgical resection is deemed unsafe. Surgical
resection of focal, well-circumscribed lesions provides not only a tissue diagnosis but also a
prolonged event-free survival in many cases.
Conventional radiation therapy has demonstrated limited efficacy in patients with focal
gliomas. Tumors with high-grade features should be treated with radiation therapy after re‐
covery from surgery or when surgery is not indicated, while low-grade tumors may be ob‐
served and treated only if there is subsequent tumor progression [5, 38]. Implantation of
iodine-129 (I-129) or iodine-125 (I-125) seeds has been used in some patients with acceptable
tumor control. I-125 is an alternative to resection, external beam radiation therapy and che‐
motherapy in children with progressively symptomatic low-grade gliomas in deep and elo‐
quent areas where high postoperative morbidity would be expected with open surgery [56].
Stereotactic radiosurgery has been used as an alternative means for managing focal brain‐
stem gliomas [57]. Its use has been reported in patients with progressive tumor growth or
worsening neurological deficits.
The role of chemotherapy has not been well evaluated for focal brainstem gliomas. In gener‐
al, for tumors that total or subtotal resection has been performed on and subsequently prog‐
ress, chemotherapy may be considered with or without radiation therapy. In children
younger than 3 years old, chemotherapy may be used alone in attempts to delay the need
for radiation therapy.
9.3. Dorsal exophytic gliomas
Dorsal exophytic gliomas are the group most amenable to surgical resection among brain‐
stem gliomas and total or near total resection alone usually results in a good prognosis [12,
20]. Long-term event-free survival is expected when these tumors are simply shaven down
to the level of the floor of the fourth ventricle. They should not be aggressively "chased" into
the brainstem. In patients with findings consistent with an obstructive hydrocephalus who
have not previously undergone a CSF diversion procedure (e.g. ETV or shunting), place‐
ment of an external ventricular drain may be considered. Tumor specimens should be sent
early for frozen sections. A high-grade lesion is an indication to halt the surgery, as there is
no proven long-term benefit to debulking aggressive lesions. Resection of the tumor takes
place primarily within the fourth ventricle on the extra-axial part. In instances where there is
a large intramedullary component to the tumor or if it is felt that damage to the functional
tissues of the brainstem would be unavoidable, subtotal resection should be attempted.
Some have advocated that resection carried to the level of the floor of the fourth ventricle
confers a sufficient balance between disease control and preservation of neurological func‐
tion by minimizing the risk of injuring functional brainstem tissues.
Radiation therapy is used for inoperable tumors or recurrent disease not amenable to re-re‐
section [5, 38]. Treatment primarily consists of conventional external beam radiation therapy
with 30-33 daily fractions of 1.8Gy/fraction [58-60]. The use of stereotactic radiation therapy
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and radiosurgery has also been examined in small cohorts. Chemotherapy has no proven ef‐
ficacy in the treatment of dorsal exophytic gliomas [61].
9.4. Cervicomedullary gliomas
Cervicomedullary  gliomas  are  treated  in  a  fashion  similar  to  that  of  an  intramedullary
spinal  cord  glioma  or  a  focal  glioma  of  the  medulla  depending  on  the  location  of  the
epicenter.  Specimens  should  be  sent  early  for  frozen  sections.  Identification  of  a  high-
grade lesion is an indication to halt the surgery, as there is no proven long-term benefit
to debulking aggressive lesions.  Surgical  resection should begin with internal  debulking
from the center to periphery.
As the majority of these tumors are low grade, surgery is typically the initial treatment mo‐
dality. Radiation therapy should be reserved for advanced or recurrent diseases not amena‐
ble to surgical resection [5, 38]. Treatment primarily consists of conventional fractionated
external beam radiation given at 1.8Gy/fraction for 30-33 fractions [58-60]. The use of stereo‐
tactic radiation therapy and radiosurgery has also been examined in small cohorts. Al‐
though a number of trials have examined the efficacy of chemotherapy in the treatment of
DIPG, no role has been defined for its use in the treatment of cervicomedullary tumors [61].
10. Outcomes
The outcome of brainstem gliomas depends on the location and pathological grade of the
tumor. Focal, dorsal exophytic and cervicomedullary gliomas typically have a fairly good
prognosis. In contrast, the median survival of DIPG patients is only about one year despite
numerous investigational therapies. In both DIPG and nondiffuse brainstem gliomas, pa‐
tients with neurofibromatosis, older age, and longer duration of symptoms before diagnosis
are thought to have a more favorable outcome [10].
10.1. Diffuse intrinsic pontine gliomas
External beam radiation therapy transiently improves the neurological condition in 85% of
DIPG patients, but the disease usually progresses within 3-4 months. No treatment has been
shown to be effective at the time of progression. Clinical deterioration is usually fast once
progression is detected. Median survival is 10-12 months. Only 10% of patients survive be‐
yond two years after diagnosis [6]. Children under the age of 3 years, young adults over 18
and those with NF1 may have a better prognosis.
10.2. Focal gliomas
Lesions typical of tectal gliomas on imaging studies usually need treatment for hydrocepha‐
lus only and rarely progress over many years. Hydrocephalus can be well managed in tectal
gliomas. ETV for tectal gliomas has a success rate exceeding 70% and as high as 90%. Focal
gliomas in other areas of the brainstem, especially if the pathology is pilocytic astrosytoma,
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can be cured by gross total resection but long-term follow-up is necessary. One study noted
a 4-year progression-free survival rate of 94% and an overall 4-year survival rate of 100% in
17 patients with focal midbrain gliomas, which included tectal gliomas [11]. Stereotactic ra‐
diosurgery may be an effective primary treatment or adjunct to open surgery for focal brain‐
stem gliomas. After gamma knife radiosurgery, most patients improved or stabilized but
some worsened [57].
10.3. Dorsal exophytic gliomas
Dorsal exophytic gliomas are amenable to surgical resection. Gross total or subtotal resec‐
tion can be achieved in most cases. They have a good outcome after surgical resection.
Among 18 patients who underwent surgery, 17 survived and only four showed evidence of
radiological progression after a median follow-up of 113 months [12]. Subsequent progres‐
sion may require re-resection or radiation therapy.
10.4. Cervicomedullary gliomas
Tumor control can be achieved by surgical resection in most patients with cervicomedullary
gliomas. 5-year progression-free survival rate is 60% and overall 5-year survival rate about
90% after surgical resection alone [14].
11. Recent advances and future directions
Because of the dismal prognosis of DIPG and the lack of therapeutic efficacy of current che‐
motherapies, innovative approach is urgently needed for the disease. One promising drug
delivery method that may improve the outcome of DIPG patients is convection-enhanced
delivery (CED). Another recent advance is the molecular characterization of DIPG, which
may provide guidance for developing new therapies.
11.1. Convection-enhanced delivery
The blood-brain barrier (BBB) presents a significant obstacle to achieving therapeutic con‐
centrations of systemically delivered agents in brain tumors. Convection-enhanced delivery
(CED) is a method of local delivery that bypasses the BBB [62]. CED is typically accomplish‐
ed by inserting a small-bore cannula directly into a tumor followed by drug infusion
through the cannula. Experimental studies have led to the recognition that CED can be char‐
acterized by several common features:
• Local drug concentration can exceed that achieved with systemic administration by sever‐
al thousand times.
• Systemic exposure by efflux into the vasculature is minimal.
• Tissue penetration by CED is well beyond that achieved by other local delivery methods
that rely on diffusion rather than bulk flow such as drug-impregnated polymers.
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• Distribution is preferentially along white matter tracts, a pattern reminiscent of glioma
cell invasion.
• CED can be used to deliver macromolecules such as monoclonal antibodies or recombi‐
nant toxins, which is not possible by systemic administration in the brain parenchyma or
tumor.
It is hypothesized that CED is ideally suited for the treatment of DIPG based on several fea‐
tures particular to this disease such as the tumor’s relative compact growth pattern, its ten‐
dency to migrate along white matter fibers, the rarity of tumor related cysts and the lack of
cavitary changes from radiation therapy.
The safety of CED in the brainstem has been well established in rodents and non-human pri‐
mates [63-71]. The tolerability of several therapeutic agents delivered using CED into the
brainstem has also been investigated and most of them proven to be safe at high concentra‐
tions [72-78]. This approach has been safely used on a limited clinical basis.
Although it is clear that certain limitations exist in the application of CED for the treatment
of DIPG, currently existing preclinical data are sufficient to guide the design of clinical stud‐
ies. Decisions in the design of these studies include the selection of an appropriate agent or
agents, surgical technique, parameters of infusion, timing of treatment and methods of as‐
sessing distribution, local concentration, safety and therapeutic efficacy. These questions,
however, should not be a barrier for clinical implementation, but rather as goals for early
phase clinical studies. Based on current preclinical data, CED may serve as the basis for a
new approach in the treatment of DIPG.
11.2. Molecular characterization of diffuse intrinsic pontine gliomas
A promising advance that may aid the development of therapeutic agents for the treatment
of DIPG is the recent molecular characterization of this tumor. Four groups independently
discovered that platelet-derived growth factor (PDGF) and its receptors (PDGFR) are ampli‐
fied or over-expressed in the majority of these tumors [22-26]. Another type of growth factor
receptors involved in DIPG is epidermal growth factor receptor (EGFR). Expression of EGFR
was reported in the majority of high grade and less than 20% of low grade DIPG by immu‐
nohistochemistry staining [27]. The same study also reported that 25% of grade III and 50%
of grade IV tumors had EGFR gene amplification. Recent data show that strong EGFR im‐
munohistochemistry staining was seen in about 27% cases [23], lower than in the earlier re‐
port, and that amplification rate of the EGFR gene is also much lower (about 7-9%) [23, 25].
Unlike the case in pediatric supratentorial HGG, CDKN2A deletion is non-existent in DIPG
[25, 28] and amplification of CDK4 and CDK6 only occurs at a low rate [25]. Approximately
50% of DIPG had p53 mutation [29, 30] and three groups reported loss of a region of 17p
containing the p53 gene in 31%, 57% and 64% cases, respectively [23, 28, 31]. In approxi‐
mately 50% of DIPG patients, allelic loss of a region of 10q where PTEN is located was ob‐
served [31-33]. Like in adult malignant gliomas, the interleukin-13 receptor subtype
IL-13Rα2 is highly expressed in DIPG [79].
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Some of these genetic aberrations have been the basis for DIPG animal models that could be
powerful tools for studying the disease, e.g., Becher et al. designed a mouse model of DIPG
based on PDGF overexpression [22]. Some of the molecular abnormalities have already been
used as therapeutic targets. There are therapeutic monoclonal antibodies targeting PDGFR,
namely IMC-3G3 (ImClone) and MEDI-575 (MedImmune), that need to be tested for efficacy
in treating DIPG, preferably delivered through CED into the tumor since they are macromo‐
lecules unable to cross the BBB. There are numerous small molecule tyrosine kinase inhibi‐
tors with strong inhibitory effects on PDGFR and/or EGFR kinases, and inhibitors of
downstream signaling molecules such as AKT and mTOR, that are undergoing clinical trials
for the treatment of DIPG. There are also targeted recombinant toxins, e.g. IL13-PE38QQR,
utilizing IL-13 as the targeting moiety to target tumor cells overexpressing IL-13 receptors.
Even though biopsy of DIPG is far from being routine, when these molecularly targeted
therapies come to clinical use, it would be ideal for the tumor to be pre-screened for specific
targets of those agents.
12. Conclusion
Brainstem gliomas are a heterogeneous group of neoplasms with considerably diverse natu‐
ral histories and prognoses. They are classified into four groups based on their location, fo‐
cality and growth patterns. Diffuse intrinsic pontine gliomas (DIPG) account for
approximately 80% of brainstem gliomas. The overwhelming majority of them is high grade.
They are not resectable and the standard of care is involved field external beam radiation
therapy. They have a dismal prognosis. The vast majority of focal, dorsal exophytic and cer‐
vicomedullary gliomas is low grade, often amenable to surgical resection and has a more fa‐
vorable outcome.
Developing effective  therapy for  DIPG is  so  far  frustrating as  neither  new schedules  of
radiation therapy nor chemotherapeutic regimens being studied have improved survival
of  these  patients.  As  better  molecular  characterization  methods  become available,  there
are increasing calls to perform biopsy and tissue diagnosis in clinically diagnosed DIPGs.
Recent molecular characterization of DIPG identified some genetic aberrations that could
be used as effective therapeutic targets,  including PDGF and PDGF receptors.  There are
both large  and small  molecule  agents  targeting these  genetic  aberrations  that  are  either
available or under development.  However,  most of  these agents are unable to cross the
blood-brain  barrier  (BBB)  to  reach the  tumor.  Convection-enhanced delivery  (CED)  is  a
drug delivery method to  bypass  the  BBB.  It  has  proven capability  to  deliver  high local
drug  concentrations  and  the  safety  of  its  use  in  the  brainstem  has  been  established  in
small  and large  animals  and a  small  number  of  patients.  CED,  combined with  conven‐
tional chemotherapeutic drugs and novel targeted agents, has the potential to produce an
effective treatment for DIPG.
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